BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.

Priscilla Kaliopi BrastianosErin TwohySusan GeyerElizabeth R GerstnerTimothy J KaufmannShervin TabriziBrian KabatJulia ThieraufMichael W RuffDaniela A BotaDavid A ReardonAdam L CohenMacarena I De La FuenteGlenn J LesserJian CampianPankaj K AgarwallaPriya KumthekarBhupinder MannShivangi VoraMichael KnoppA John IafrateWilliam T CurryDaniel P CahillHelen A ShihPaul D BrownSandro SantagataFred G BarkerEvanthia Galanis

Published in: The New England journal of medicine (2023)

In this small, single-group study involving patients with papillary craniopharyngiomas, 15 of 16 patients had a partial response or better to the BRAF-MEK inhibitor combination vemurafenib-cobimetinib. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT03224767.).

Keyphrases

newly diagnosed
end stage renal disease
ejection fraction
pi k akt
prognostic factors
peritoneal dialysis
metastatic colorectal cancer
clear cell